An insight into the mechanism of Salvia miltiorrhiza intervention on osteoporosis based on network pharmacology

doi:10.3969/j.issn.2095-4344.3014

Abstract

Abstract: BACKGROUND: Salvia miltiorrhiza has been widely used in the treatment of osteoporosis in recent years, but its mechanism in human body is not clear.
OBJECTIVE: To screen the main active components of Salvia miltiorrhiza and their corresponding targets by the method of network pharmacology, to construct the active components-action target-disease network of traditional Chinese medicine, and to explore the mechanism of Salvia miltiorrhiza in the treatment of osteoporosis.
METHODS: Firstly, the main active components and related targets of Salvia miltiorrhiza were selected based on the characteristics of pharmacokinetics in the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP), and then the known therapeutic targets of osteoporosis were screened from the Online Mendelian Inheritance in Man (OMIM) and GeneCards database. The Salvia miltiorrhiza target and osteoporosis target were intersected to obtain the common target of traditional Chinese medicine and disease. The traditional Chinese medicine-active ingredient-target-disease regulation network was topologically constructed by using Cytoscape software, and the protein-protein interaction network and bar graph of traditional Chinese medicine-disease target were constructed by using String database to screen the core targets. Finally, the traditional Chinese medicine-disease target was analyzed by GO functional enrichment analysis and KEGG pathway enrichment analysis.
RESULTS AND CONCLUSION: A total of 65 active ingredients of Salvia miltiorrhiza, 932 related targets, 3 264 disease targets, and 74 Chinese medicine-disease interaction targets were obtained through screening. The analysis based on network pharmacology indicated that the potential active ingredients of Salvia miltiorrhiza in treating osteoporosis mainly include luteolin, tanshinone IIa, cryptotanshinone, etc. These components can activate target proteins such as AKT1, interleukin-6, vascular endothelial growth factor A, and MAPK1 to activate PI3K-Akt, interleukin-17, hypoxia-inducible factor-1, AGE-RAGE signaling pathway in diabetic complications. These activated signaling pathways can directly or indirectly participate in cell differentiation and apoptosis, metabolism, oxidative stress, and inflammatory response in the treatment of osteoporosis. The role of Salvia miltiorrhiza can be further confirmed by its multi-component, multi-target, and multi-system effects on osteoporosis. However, the above conclusions and specific mechanism of action need to be further studied.

Key words: Salvia miltiorrhiza, osteoporosis, network pharmacology, action mechanism

CLC Number:

Xiao Fangjun, Chen Shudong, Luan Jiyao, Hou Yu, He Kun, Lin Dingkun. An insight into the mechanism of Salvia miltiorrhiza intervention on osteoporosis based on network pharmacology[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(5): 772-778.

Figures/Tables 12

References

[1] 张智海,刘忠厚,李娜,等.中国人骨质疏松症诊断标准专家共识[J].中国骨质疏松杂志,2014, 20(9):1007-1010.
[2] 胡军,张华,牟青.骨质疏松症的流行病学趋势与防治进展[J].临床荟萃,2011,26(8):729-731.
[3] 单祎娜,王莉.骨质疏松症诊断和治疗进展[J].医学综述,2019,25(18):3652-3661.
[4] 仇宋明,尹恒,王建伟.基于“脾肾相关”论治疗骨质疏松症的研究进展[J].中国骨质疏松杂志,2019,25(12):1809-1816.
[5] 高子任,李跃华.中医血瘀证与骨质疏松症关系的研究[J].中华中医药杂志,2017,32(11): 5154-5157.
[6] 郭鱼波,王丽丽, 马如风, 等.骨质疏松的中医病因病机分析及其中医药治疗的前景探讨[J].世界科学技术—中医药现代化,2015,17(4):768-772.
[7] 阎博昭,李刚,许波,等.丹参治疗股骨头坏死的分子机制研究[J].安徽中医药大学学报,2018, 37(5):62-68.
[8] 白璧辉,谢兴文,黄晋,等.丹参及其有效成分防治骨质疏松症研究概况[J]. 中医药临床杂志, 2018,30(5):813-816.
[9] 莫朝伦,张军梅,贾莹, 等.丹参酮Ⅱ-A 对大鼠成骨细胞体外增殖分化的影响[J].贵阳医学院学报,2016,41(4):391-394.
[10] 桑龙,韩红德,吴克第, 等.丹参素通过核因子κB受体活化因子配体通路抑制破骨细胞分化治疗大鼠骨质疏松症的研究[J].中国临床药理学杂志,2019,35(23):3072-3076.
[11] 陈海彬,周红光,李文婷,等. 网络药理学——中药复方作用机制研究新视角[J].中华中医药杂志,2019,34(7):2873-2876.
[12] PEI T, ZHENG C, HUANG C, et al. Systematic understanding the mechanisms of vitiligo pathogenesis and its treatment by Qubaibabuqi formula.J Ethnopharmacol. 2016;190:272-287.
[13] 甘东浩,薛海鹏,陈德强,等.基于网络药理学探讨骨碎补抗骨质疏松的物质基础及作用机制[J].中国实验方剂学杂志,2019,25(13):186-191.
[14] MOMOTA R, OHTSUKAA. Network of anatomical texts(NAnaTex),an open-source project for visualizing the interaction between anatomical terms.Anat Science Int.2018;93(1):149-153.
[15] FRANCESCHINI A, SZKLARCZYK D, FRANKILD S, et al.STRING V9.1: Protein-Protein Interaction Networks, with Increased Coverage and Integration.Nucleic Acids Res. 2013;41(Database issue):D808-815.
[16] 徐森楠,庄莉,翟园园,等,基于网络药理学研究二至丸防治骨质疏松症的物质基础与作用机制[J].中国药学杂志,2018.53(22): 1913-1920.
[17] JING Z, WANG C, YANG Q, et al. Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro.J Cell Physiol. 2019;234(4):4472-4490.
[18] 郭威,李谌,李全营,等.丹参酮ⅡA对大鼠骨髓间充质干细胞成骨分化的影响[J].山东医药,2011,51(44):38-40.
[19] 曾克勤,武剑,强红伟,等.从瘀论治系统性红斑狼疮继发性骨质疏松症[J]. 中医学报, 2019, 34(248):199-203.
[20] 王雪鹏,李茂强,边振宇,等.PI3K/Akt信号通路在骨髓间充质干细胞增殖及成骨分化调控中的作用[J].中华骨质疏松和骨矿盐疾病杂志, 2014,7(3):250-257.
[21] CHEN LL, HUANG M, TAN JY, et al. PI3K/AKT pathway involvement in the osteogenic effects of osteoclast culture supernatants on preosteoblast cells.Tissue Eng Part A.2013;19:2226-2232.
[22] CZERNY B, KAMINSKI A, KURZAWSKI M, et al. The association of IL-1β, IL-2, and IL-6 gene polymorphisms with bone mineral density and osteoporosis in postmenopausal women.Eur J Obstet Gynecol Reprod Biol.2010;149(1):82-85.
[23] 尚国伟.小鼠骨髓间质干细胞成骨分化及促肾上腺皮质激素的影响[D].郑州:郑州大学,2014: 1-52.
[24] 张波,耿彬,谭小义,等.MAPK信号通路与骨质疏松关系的研究进展[J].中国矫形外科杂志, 2014, 22(23):2161-2164.
[25] 徐会金.运动通过p38MAPK信号通路对2型糖尿病小鼠骨代谢的影响[D].上海:华东师范大学, 2016.
[26] 陈亚辉,龚忠勤,崔燎.PI3K/Akt信号通路在骨质疏松病理过程中的作用[J].中国骨质疏松杂志, 2015,21(3):356-360.
[27] 高润涛,范志朋.丹参注射液促进人脱落乳牙牙髓干细胞成骨/成牙分化的实验研究[J].北京口腔医学,2018,26(2):65-68.
[28] ADAPALA NS,BARBE MF,TSYGANKOV AY,et al.Loss of Cbl-PI3K interaction enhances osteoclast survival due to p21-R as mediated PI3K activation independent of Cbl-b.J Cell Biochem.2014;115(7): 1277-1289.
[29] NAKCHBANDI IA.Osteoporosis and fractures in liver disease: Relevance, pathogenesis and therapeutic implications.World J Gastroenterol. 2014; 20(28): 9427- 9438.
[30] WIJARNPREECHA K, THONGPRAYOON C, PANJAWATANAN P, et al. Hepatitis C Virus Infection and Risk of Osteoporosis: A Meta-analysis. Gastroenterology. 2017;23:216-221.
[31] 黄陈恕,汤荣睿,易小翠.慢性乙型肝炎与骨质疏松相关性初步探讨[J].中国骨质疏松杂志. 2016.22(9):1136-1139.
[32] 黄英,杨颜茹.丙型肝炎后肝硬化与骨质疏松的临床研究[J].吉林医学,2012,33(23):4938-4939.
[33] 刘攀,姜睿.前列腺癌骨病诊断和治疗的进展[J].临床泌尿外科杂志,2016,31(8):762-766.
[34] HOFBAUER LC,RACHNER TD,COLEMAN RE,et al.endocrine asoects of bone metastases.Lancet Diabetes Endocrinol. 2014;2(6):500-502.
[35] YUAN FL,LI X,LU WG,et al.Type 17 T-helper cells might be a promising therapeutic target for osteoporosis.Mol Biol Rep. 2012;39(1):771-774.
[36] TYAGI AM, SRIVASTAVA K, MANSOORI MN, et al. Estrogen Deficiency Induces the Differentiation of IL-17 Secreting Th17 Cells: A New Candidate in the Pathogenesis of Osteoporosis.PLoS One. 2012; 7(9):e44552.
[37] 刘海.类风湿性关节炎并发骨质疏松患者骨密度、骨代谢指标与血清 IL-17、MMP-9水平的关系[J].河北医药,2015,37(17):2576-2579.
[38] 钟航,曹参,杨静,黄强.HIF-1信号通路与绝经后骨质疏松的关系研究[J].四川大学学报(医学版),2017,48(6):862-868.
[39] 黄文舟,殷嫦嫦,敖鹏, 等,晚期糖基化终末产物与骨性关节炎相关性的研究进展[J].中国矫形外科杂志,2017,25(9):820-823.
[40] REYNAERT NL, GOPAL P, RUTTEN EPA, et al. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to diseas.Int J Biochem Cell Biol.2016;81(Pt B): 403-418.
[41] Li G, Xu J, Li Z. Receptor for advanced glycation end products inhibits proliferation in osteoblast through suppression of Wnt, PI3K and ERK signaling.Biochemical and biophysical research communications 2012;423(4):684-689.